. Author manuscript; available in PMC: 2008 Dec 4.

Published in final edited form as: Biochemistry. 2006 Oct 3;45(39):11895–11904. doi: 10.1021/bi060990m

Table 2.

Characteristics of the main enamine feature given by the three clinical inhibitors used with two variants (E166A and M69V-E166A) of SHV-1 β-lactamase

	Tazobactam derived enamine ±2 cm⁻¹	Sulbactam derived enamine± 2 cm⁻¹	Clavulanic acid derived enamine± 2 cm⁻¹
Enamine peak Raman shift for various inhibitors with E166A/M69V-E166A β-lactamase	1593/1593 cm⁻¹	1599/1601 cm⁻¹	1612/1610 cm⁻¹
Enamine peak width of various inhibitors with E166A SHV-1 β-lactamase	18 cm⁻¹	25 cm⁻¹	32 cm⁻¹
Enamine peak width of various inhibitors with M69V-E166A SHV-1 β-lactamase	18 cm⁻¹	28 cm⁻¹	34 cm⁻¹